Maxim analyst Anthony Vendetti lowered the firm’s price target on Sientra to $5 from $7 but keeps a Buy rating on the shares. The analyst cites the company Q4 revenue, gross margin, and earnings coming in below consensus and the firm’s forecast, even though the gross margin included non-cash expenses related to inventory reserves and warranty liability that kept it from topping its estimates. Maxim adds that despite the slight revenue miss, it is encouraged by the continued market share gains in the breast market, the addition of roughly 275 new accounts during the quarter, and the potential of the recently launched Viality fat grafting device.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SIEN:
- Sientra Reports Record Fourth Quarter and Full Year Revenues and Expands Total Addressable Market With New Product Launches
- Sientra (SIEN) Q4 Earnings Cheat Sheet
- Aziyo Biologics, Sientra team on SimpliDerm for soft tissue reconstruction
- Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
- Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer System